All News
Elevated Uric Acid Is Associated With New‐Onset Atrial Fibrillation
A Longitudinal Swedish study has shown that elevated serum uric acid (SUA) levels has cardiovascular implications and may predict the development of atrial fibrillation (AFib).
Read Article
Worldwide prevalence (major markets) of #RA was 4.9 million in 2020; the RA global treatment market is estimated at US $40.5 billion in 2021, and is expected to grow ~6% per year in the next decade. https://t.co/EtBQwru0uF https://t.co/BRLtnwxc2b
Links:
Dr. John Cush RheumNow ( View Tweet)
Causes of Enthesitis: SpA (AS, reactive arthritis, PsA, enteropathic arthritis, ERA), JIA, but also in RA, leprosy, trauma, OA, DISH, acromegaly, fluorosis, retinoid therapy, hypo- or hyper-PTH, POEMS syndrome, X-linked hypophosphatemia https://t.co/9NjlIExl8c https://t.co/vaRJjwOu2q
Links:
Dr. John Cush RheumNow ( View Tweet)
Enthesitis portends worse SpA. Data from 749 SpA pts in REGISPONSER-AS registry found 6.1% w/achilles tendinitis at baseline. Pts w/ enthesitis had worse pain, BASDAI, mBASDAI, ASDAS-CRP scores & after 2 yrs had fewer in low dz state (16 vs 31.5%) https://t.co/sChQ4WFmlW https://t.co/BkjzxCQIGF
Links:
Dr. John Cush RheumNow ( View Tweet)
RA Disease Activity and Alcohol Use
The effects of alcohol use in RA is less known, but a study suggests that alcohol consumption was dose-dependently associated with lower disease activity and higher health-related quality of life in RA patients.
https://t.co/u6ZjZ7o1Hq https://t.co/S9JPXMJVZo
Links:
Dr. John Cush RheumNow ( View Tweet)
AR882, selective uric acid transporter 1 (URAT1) inhibitor in development, completed a phase 2, 140 pt 12-week PBO controlled trial, where 75 mg/d lowered SUA by 59% (8.6 to 3.5 ) & 42% (8.6 to 5.0 ) in 50 mg dose group - all better than PBO https://t.co/HHzHWj4XQr https://t.co/gJD9hnkFJc
Links:
Dr. John Cush RheumNow ( View Tweet)
How would you treat 37yoF B27+ AS on Taltz, now pregnant?(Failed NSAIDs, TNFi's)
Dr. John Cush RheumNow ( View Tweet)
Join RheumNow Live in person or virtually on 3/18 and 3/19. This meeting is unlike any other meeting you attended.
But don't take our word for it, last year's attendees say:
"Great conference. Best in the last year. I did Hopkins, CCR, and ACR too"
https://t.co/Im6xStFwOw https://t.co/NhdbkNo1jl
Links:
Dr. John Cush RheumNow ( View Tweet)
Ferritin may be more than biomarker in Stills, etc - may contribute directly to pathogenesis. Ferritin causes PMN activation & neutrophil extracellular traps (NETs). Could this be targeted therapeutically? https://t.co/tHbS6WtNWp https://t.co/rXfqgkij7k
Dr. John Cush RheumNow ( View Tweet)
Worse Birth Outcomes in RA and SLE
A population-based retrospective cohort study patients with RA or SLE and their infants demonstrated significant adverse pregnancy outcome, particularly the infants of women with SLE.
https://t.co/oK05W8ncW0 https://t.co/3eJzHHOvXO
Links:
Dr. John Cush RheumNow ( View Tweet)
Half of all outpt. MDs are bound by restrictive covenants. FTC is considering a ban on noncompete clauses. AMA) code of ethics discourages covenants that "unreasonably restrict". FTC the rule change could save Pts up to $148 billion https://t.co/nssfbrxnLR https://t.co/8hGArfGEGW
Links:
Dr. John Cush RheumNow ( View Tweet)
173 PsA pts enrolled to start ustekinumab: half on MTX and half on PBO. At week 24 there was no difference in DAS28 between groups (2.9 vs 3.1); then Ustekinumab plus placebo was non-inferior to ustekinumab plus methotrexate https://t.co/AygtawIZsZ https://t.co/YLGp5lMWT9
Links:
Dr. John Cush RheumNow ( View Tweet)
ACP Guidelines on Fracture Prevention in at-risk Adults
The American College of Physicians (ACP) has updated its 2017 recommendations on pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults.
https://t.co/e7qaNCXUnx https://t.co/yys4MXMyOd
Links:
Dr. John Cush RheumNow ( View Tweet)
Free great handout on DRESS - Drug Reaction With Eosinophilia and Systemic Symptoms. May affect adults or children; usually 2 to 8 weeks after beginning a medication. ~1 in 1000 taking specific drugs get DRESS. Allopurinol is a common cause https://t.co/gTW8D3raHV https://t.co/aQbnFS3rNR
Links:
Dr. John Cush RheumNow ( View Tweet)
anti-mitochondrial antibodies (AMA) in were assayed in 404 #RA patients & found to positive in 14-26%. Importantly AMA Abs were associated with erosive disease (p<0.05) and interstitial lung disease (p<0.01), independent of CCP or RF https://t.co/TW2xsa1igt https://t.co/jr1ltgGmdF
Links:
Dr. John Cush RheumNow ( View Tweet)
AutoAb analysis of 140 systemic sclerosis shows low sensitivity (<33%), high specificity (>88%). Scl-70+ signif assoc w sine scleroderma, digital ulcers, Raynauds as 1st onset sign. SSc-ILD more common Scl-70 and PAH with CENP A/B Abs https://t.co/ZQksWVauMZ https://t.co/RKSWOItdxu
Links:
Dr. John Cush RheumNow ( View Tweet)
Evidence based Latin American Guidelines of clinical practice on prevention, diagnosis, management and treatment of glucocorticoid induced osteoporosis. A 2022 update https://t.co/CmYnENB60W https://t.co/Qm5hR1fCx6
Links:
Dr. John Cush RheumNow ( View Tweet)
Neutrophil-to-lymphocyte ratio (NLR) was studied in 205 Idiopathic pulmonary fibrosis (IPF) pts - NLR correlated with lung function, & outcomes - NLR >= 2.9 was associated with a significant 2 fold increased risk of mortality https://t.co/FwnfrVW29M https://t.co/BIX8e3svJB
Links:
Dr. John Cush RheumNow ( View Tweet)
Hosp study of 2809 admissions, found 1+adverse events (AE) in 24%. Among 978 AE, 23% (222) were preventable; 32% (316) serious. Preventable AE occurred in 1/15 admissions (serious 1/100). Drug AE were most common (39%) https://t.co/YKaYgmRbLN
Links:
Dr. John Cush RheumNow ( View Tweet)
Join us on 3/18 and 3/19 in Dallas, Texas or virtually for RheumNow Live!
RheumNow Live is unlike any meeting you've ever attended. Here's why:
-Inspired Education
-The Audience Matters
-Never Seen Before
https://t.co/qKoBckRNK1 https://t.co/2tyLsxV0L7
Links:
Dr. John Cush RheumNow ( View Tweet)
